Organogenesis Q2 2026 earnings: Wound care decline compresses margins

Organogenesis (Nasdaq: ORGO) reported Q2 2026 net product revenue of $42.8 million, down 58% from $100.8 million a year earlier, while diluted loss per share widened to $0.77 from $0.10. Advanced Wound Care accounted for nearly all of the revenue decline, contributing to a sharp gross-margin contraction and a larger operating loss.

Core earnings data

The results cover the three months ended June 30, 2026. Total revenue was $43.8 million after including $950,000 of grant income, but the company’s primary operating measure was net product revenue of $42.8 million.

Gross profit fell faster than revenue as gross margin contracted by 28 percentage points. Lower selling, general and administrative expenses provided only a partial offset, while R&D spending increased.

Adjusted net loss was $89.0 million, compared with $7.5 million a year earlier. The non-GAAP calculations excluded items including restructuring charges, R&D program termination costs and a fair-value adjustment related to a building classified as held for sale.

Business and segment performance

Advanced Wound Care was the primary source of weakness. Its $56.6 million revenue decline represented about 98% of the company’s total year-over-year decrease in net product revenue.

Surgical & Sports Medicine also contracted, but its 18% decline was considerably smaller than the drop in Advanced Wound Care. Management characterized the broader environment as a significant market contraction and said the recovery was proceeding more slowly than previously expected.

Revenue contraction overwhelmed cost reductions

Organogenesis reduced reported operating expenses by $18.8 million, or 17%, including a $19.8 million reduction in SG&A. Those savings were insufficient to offset the $54.0 million decline in gross profit, while R&D expense increased by $7.9 million. As a result, operating loss expanded to $51.0 million.

The GAAP net loss was substantially larger than the operating loss because the company recorded $45.4 million of income tax expense, compared with a $2.4 million tax benefit in Q2 2025. However, the deterioration was not limited to tax accounting: adjusted EBITDA loss also widened by $30.7 million to $34.4 million.

Cash flow and balance sheet

Cash-flow figures were reported for the first six months rather than Q2 alone. Operating cash outflow improved to $10.5 million for the six months ended June 30, 2026, from $52.8 million a year earlier, an improvement of about $42.3 million despite the much larger net loss.

A $119.5 million cash inflow from changes in accounts receivable was the largest working-capital offset. Accounts receivable fell to $100.9 million at June 30 from $217.5 million at the end of 2025.

Cash, cash equivalents and restricted cash nevertheless declined from $94.3 million at year-end to $46.8 million. In addition to operating cash use, the company spent $4.2 million on property and equipment and used $32.7 million in financing activities, including $19.5 million for construction of landlord assets and $10.2 million of finance-lease principal repayments. Organogenesis reported no outstanding debt obligations at quarter-end.

Fiscal 2026 guidance

Organogenesis updated its 2026 outlook to reflect a slower recovery than assumed in its prior guidance. The company still expects sequential revenue improvement in the third and fourth quarters, but at a more measured pace.

The full-year comparison is against 2025 net revenue of $564.2 million. The wider expected second-half decline indicates that the company no longer anticipates the pace of improvement embedded in its previous outlook.

Management’s view

President, CEO and board chair Gary S. Gillheeney Sr. said Q2 showed signs of measured improvement, but acknowledged that recovery from the market contraction was slower than expected. Management continues to emphasize the company’s evidence-based regenerative medicine portfolio and is advancing the ReNu program as a potential route into new markets.

Recent insider transactions

Separate insider transaction data showed two direct purchases by directors in March 2026 and two larger sales by director Glenn H. Nussdorf in late 2025. These transactions are presented without inferring insider views about the company’s prospects.

Risks investors need to monitor

• A slower-than-expected market recovery: The updated outlook assumes second-half revenue will decline approximately 64% to 74%, materially worse than the prior 45% to 52% decline assumption.
• Dependence on Advanced Wound Care: This segment produced most of the quarterly revenue decline, leaving consolidated results highly exposed to its demand and reimbursement environment.
• Margin and cost pressure: Gross margin fell to 45% from 73%. Although SG&A declined, the reduced gross-profit base and higher R&D spending continued to produce substantial operating losses.
• Liquidity consumption: First-half operating cash flow improved, but cash, cash equivalents and restricted cash still fell by $47.5 million from year-end to $46.8 million.
• Coverage and regulatory uncertainty: The company identified changes in CMS reimbursement and coverage, as well as the need to secure approval and successfully commercialize ReNu, as material risks.

Summary

Organogenesis’ Q2 2026 results were defined by a 61% decline in Advanced Wound Care revenue, significant gross-margin compression and losses that expanded despite lower SG&A spending. First-half operating cash use improved due mainly to accounts-receivable movements, but the cash balance declined substantially. The central issue for upcoming quarters is whether sequential revenue improvement materializes at the slower pace now reflected in fiscal 2026 guidance.